Catalyst Wire Dossier Catalyst Wire Dossier

Autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases

· Sangamo Therapeutics
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases, covering 2019-09-20 to 2019-09-20. Get the full timeline:

Most recent: Clinical Trial Update: Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects [Phase 1, Phase 2]

See pricing